Mankind Pharma Q4 Results: Cons PAT jumps 50% YoY to Rs 285 crore, sales up 19%

For FY23, the company reported a 11% drop in consolidated net profit to Rs 1,282 crore, despite a 12.4% growth in revenue to Rs 8,749 crore.